BioWorld

Feb. 4, 2005

Valeant Buying Out Xcel's Neurology Line For $280M

About this time last year, Xcel Pharmaceuticals Inc. bought the rights to the Phase III-ready epilepsy drug retigabine from Viatris GmbH and Co., of Frankfurt, Germany. (BioWorld Today) Read More

Bioenvision Brings In $60M; Favrille, Icagen Make Debuts

Myogen's Stock Drops On Delay In Ambrisentan Trial

Xcyte's Shares Slump As FDA Seeks To Rework Trial Plans

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 12, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 12, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Illustration of head with maze that is missing parts

CTAD 2025: The challenges of combination therapies for dementia

BioWorld Science

At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...

Illustration of motor neuron connecting to muscle fiber

Research grants support early clinical trials of ALS treatments

BioWorld Science

The ALS Association has announced the recipients of its 2025 Hoffman ALS Clinical Trial Awards. These research grants, worth up to $1 million each, support...